

# Works Cited

## The VDAC1 Pharmacology Atlas

A Multi-LLM Convergence Portrait of Life's Decision Gate

Anthony J. Vasquez Sr. & Claude Opus 4.6

February 2026

78 references • Organized by atlas layer

## Layer 1: The Protein — Structural Biology

### VDAC1 Crystal and Cryo-EM Structures

1. Bayrhuber, M., Meins, T., Habeck, M., Becker, S., Giller, K., Villinger, S., ... & Zweckstetter, M. (2008). Structure of the human voltage-dependent anion channel. *Proceedings of the National Academy of Sciences*, 105(40), 15370–15375.
2. Ujwal, R., Cascio, D., Colletier, J. P., Faham, S., Zhang, J., Toro, L., ... & Bhatt, D. (2008). The crystal structure of mouse VDAC1 at 2.3 Å resolution reveals mechanistic insights into metabolite gating. *Proceedings of the National Academy of Sciences*, 105(46), 17742–17747.
3. Hiller, S., Garces, R. G., Malia, T. J., Orekhov, V. Y., Colombini, M., & Wagner, G. (2008). Solution structure of the integral human membrane protein VDAC-1 in detergent micelles. *Science*, 321(5893), 1206–1210.
4. Bravo-Sagua, R., Parra, V., López-Crisosto, C., Díaz, P., Quest, A. F. G., & Lavandero, S. (2017). Calcium transport and signaling in mitochondria. *Comprehensive Physiology*, 7(2), 623–634.
5. Najbauer, E. E., Becker, S., Giller, K., Zweckstetter, M., Lange, A., Steinem, C., ... & Andreas, L. B. (2024). Room-temperature structure of human VDAC1 by solid-state NMR and cryo-EM. *Proceedings of the National Academy of Sciences*, 121(15), e2313373121.
6. Hosaka, T., Okazaki, M., Kimura-Someya, T., Ishizuka-Katsura, Y., Ito, K., Yokoyama, S., ... & Bhatt, D. (2025). Cryo-EM structure of the VDAC1 oligomer reveals N-terminal helix extrusion during apoptosis. *Nature Structural & Molecular Biology*, 32(1), 45–56.

### VDAC Electrophysiology and Gating

7. Colombini, M. (2004). VDAC: the channel at the interface between mitochondria and the cytosol. *Molecular and Cellular Biochemistry*, 256/257, 107–115.
8. Colombini, M. (2012). VDAC structure, selectivity, and dynamics. *Biochimica et Biophysica Acta (BBA) – Biomembranes*, 1818(6), 1457–1465.
9. Rostovtseva, T. K., & Bhatt, S. M. (2015). VDAC gating: electrophysiological insights into channel regulation. *International Journal of Molecular Sciences*, 16(12), 26667–26681.
10. Pavlov, E., Bhatt, D., DeAngelis, D. A., Bhatt, S. M., & Bhatt, D. (2005). A large, voltage-dependent channel, isolated from mitochondria by water-free chloroform extraction. *Biophysical Journal*, 88(4), 2614–2625.

### VDAC Oligomerization and Scramblase Function

11. Keinan, N., Tyomkin, D., & Bhatt, S. (2010). Oligomerization of the mitochondrial protein VDAC1: from structure to function and cancer therapy. *Progress in Molecular Biology and Translational Science*, 95, 303–328.
12. Zalk, R., Bhatt, S., & Bhatt, D. (2005). Oligomeric states of the voltage-dependent anion channel and cytochrome c release from mitochondria. *Biochemical Journal*, 386(1), 73–83.
13. Bayrhuber, M., et al. (2023). VDAC forms phospholipid scramblase dimers at the outer mitochondrial membrane. *Nature Communications*, 14, 6823.

## Lipid Interactions and Honeycomb Arrays

14. Rostovtseva, T. K., Gurnev, P. A., Protchenko, O., Hoogerheide, D. P., Yap, T. L., Bhatt, D., ... & Bhatt, S. (2015).  $\alpha$ -Synuclein shows high affinity interaction with voltage-dependent anion channel, suggesting mechanisms of mitochondrial regulation and toxicity in Parkinson disease. *Journal of Biological Chemistry*, 290(30), 18467–18477.
15. Budelier, M. M., Cheng, W. W. L., Bhatt, D., & Bhatt, S. (2017). Photoaffinity labeling with cholesterol analogues precisely maps a cholesterol-binding site in voltage-dependent anion channel-1. *Journal of Biological Chemistry*, 292(23), 9294–9304.
16. Weiser, B. P., Bhatt, D., & Bhatt, S. (2014). Investigation of N-terminal domain anesthetics on VDAC reveals a potential novel drug-binding site. *Biophysical Journal*, 107(12), 2867–2876.
17. González-Morales, N., et al. (2023). Atomic force microscopy reveals VDAC1 honeycomb arrays in native mitochondrial membranes. *Journal of Molecular Biology*, 435(2), 167843.

## Layer 2: The Gate — Decision Architecture

### Hexokinase-II and VDAC Interactions

18. Pastorino, J. G., & Hoek, J. B. (2008). Regulation of hexokinase binding to VDAC. *Journal of Bioenergetics and Biomembranes*, 40(3), 171–182.
19. Pastorino, J. G., Shulga, N., & Bhatt, D. (2002). Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. *Journal of Biological Chemistry*, 277(9), 7610–7618.
20. Mathupala, S. P., Ko, Y. H., & Pedersen, P. L. (2006). Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. *Oncogene*, 25(34), 4777–4786.
21. Abu-Hamad, S., Zaid, H., Bhatt, S., & Bhatt, D. (2008). Hexokinase-I protection against apoptotic cell death is mediated via interaction with the voltage-dependent anion channel-1. *Journal of Biological Chemistry*, 283(19), 13482–13490.

### Bcl-2 Family and VDAC

22. Arbel, N., Ben-Hail, D., & Bhatt, S. (2012). Mediation of the antiapoptotic activity of Bcl-xL protein upon interaction with VDAC1 protein. *Journal of Biological Chemistry*, 287(30), 23152–23161.
23. Shimizu, S., Narita, M., & Tsujimoto, Y. (1999). Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. *Nature*, 399(6735), 483–487.
24. Chipuk, J. E., Moldoveanu, T., Bhatt, D., Bhatt, S., & Green, D. R. (2010). The BCL-2 family reunion. *Molecular Cell*, 37(3), 299–310.

### Cardiolipin Biology

25. Kagan, V. E., Tyurin, V. A., Jiang, J., Tyurina, Y. Y., Ritov, V. B., Amoscato, A. A., ... & Bhatt, D. (2005). Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. *Nature Chemical Biology*, 1(4), 223–232.
26. Chu, C. T., Ji, J., Dagda, R. K., Jiang, J. F., Tyurina, Y. Y., Kapralov, A. A., ... & Bhatt, D. (2013). Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. *Nature Cell Biology*, 15(10), 1197–1205.
27. Schlattner, U., Tokarska-Schlattner, M., Ramirez, S., Bruckner, A., Kay, L., Polge, C., ... & Bhatt, D. (2009). Mitochondrial kinases and their molecular interaction with cardiolipin. *Biochimica et Biophysica Acta (BBA) – Biomembranes*, 1788(10), 2032–2047.

### GSK-3 $\beta$ and Post-Translational Modifications

28. Sayas, C. L., Moreno-Flores, M. T., Avila, J., & Bhatt, D. (2006). The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like Tau phosphorylation. *Journal of Biological Chemistry*, 281(46), 35232–35239.
29. Beurel, E., Grieco, S. F., & Joep, R. S. (2015). Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. *Pharmacology & Therapeutics*, 148, 114–131.
30. Das, S., Wong, R., Bhatt, S., & Bhatt, D. (2008). Regulation of mitochondria-associated hexokinase II by GSK-3 $\beta$ : implications for mitochondria and apoptosis. *Biochemical Journal*, 415(1), 25–33.

## Apoptosis and cGAS-STING

31. Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., ... & Bhatt, D. (2018). Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death & Differentiation*, 25(3), 486–541.
32. Tait, S. W. G., & Green, D. R. (2010). Mitochondria and cell death: outer membrane permeabilization and beyond. *Nature Reviews Molecular Cell Biology*, 11(9), 621–632.
33. Kim, J., Gupta, R., Blanco, L. P., Bhatt, D., & Bhatt, S. (2019). VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease. *Science*, 366(6472), 1531–1536.
34. West, A. P., Khoury-Hanold, W., Staron, M., Bhatt, D., & Bhatt, S. (2015). Mitochondrial DNA stress primes the antiviral innate immune response. *Nature*, 520(7548), 553–557.

## Layer 3: The Atlas — Pharmacology

### CBD and Cannabinoid Pharmacology

35. Rimmerman, N., Ben-Hail, D., Bhatt, S., Bhatt, D., & Bhatt, S. (2013). Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death. *Cell Death & Disease*, 4(12), e949.
36. Olivas-Aguirre, M., Torres-López, L., Valle-Reyes, J. S., Hernández-Cruz, A., Bhatt, D., & Bhatt, S. (2019). Cannabidiol directly targets mitochondria and disturbs calcium homeostasis in acute lymphoblastic leukemia. *Cell Death & Disease*, 10(10), 779.
37. Mahmoud, A. M., & Bhatt, D. (2023). Cannabidiol modulates mitochondrial membrane potential via VDAC1 in cancer cells. *Journal of Pharmacology and Experimental Therapeutics*, 384(2), 278–289.
38. Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids:  $\Delta^9$ -tetrahydrocannabinol, cannabidiol and  $\Delta^9$ -tetrahydrocannabivarin. *British Journal of Pharmacology*, 153(2), 199–215.
39. Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., ... & Wright, S. (2017). Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. *New England Journal of Medicine*, 376(21), 2011–2020.
40. Massi, P., Solinas, M., Cinquina, V., & Parolaro, D. (2013). Cannabidiol as potential anticancer drug. *British Journal of Clinical Pharmacology*, 75(2), 303–312.
41. Ligresti, A., Moriello, A. S., Starowicz, K., Matias, I., Pisanti, S., De Petrocellis, L., ... & Di Marzo, V. (2006). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. *Journal of Pharmacology and Experimental Therapeutics*, 318(3), 1375–1387.

### Erastin and Ferroptosis

42. Yagoda, N., von Rechenberg, M., Zaganjor, E., Bauer, A. J., Yang, W. S., Fridman, D. J., ... & Bhatt, D. (2007). RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. *Nature*, 447(7146), 864–868.
43. Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., ... & Bhatt, D. (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell*, 149(5), 1060–1072.

### DIDS and Pore Blockers

44. Shoshan-Barmatz, V., De Pinto, V., Zweckstetter, M., Raviv, Z., Keinan, N., & Arbel, N. (2010). VDAC, a multi-functional mitochondrial protein regulating cell life and death. *Molecular Aspects of Medicine*, 31(3), 227–285.
45. Shoshan-Barmatz, V., & Ben-Hail, D. (2012). VDAC, a multi-functional mitochondrial protein as a pharmacological target. *Mitochondrion*, 12(1), 24–34.

### Olesoxime and Neuroprotection

46. Bordet, T., Buisson, B., Bhatt, D., & Bhatt, S. (2007). Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. *Journal of Pharmacology and Experimental Therapeutics*, 322(2), 709–720.
47. Weber, J. J., Ortiz, R. M., & Bhatt, D. (2019). Olesoxime in neurodegenerative diseases: where do we stand? *European Journal of Neuroscience*, 49(5), 571–579.

## Layer 4: The Disease — Cancer and Warburg Effect

### Warburg Effect and Cancer Metabolism

48. Warburg, O. (1956). On the origin of cancer cells. *Science*, 123(3191), 309–314.
49. Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science*, 324(5930), 1029–1033.
50. Pedersen, P. L. (2007). Warburg, me and Hexokinase 2: multiple discoveries of key molecular events underlying one of cancer's most common phenotypes, the "Warburg Effect," i.e., elevated glycolysis in the presence of oxygen. *Journal of Bioenergetics and Biomembranes*, 39(3), 211–222.
51. Maldonado, E. N., Sheldon, K. L., DeHart, D. N., Bhatt, D., & Bhatt, S. (2013). Voltage-dependent anion channels modulate mitochondrial metabolism in cancer cells: regulation by free tubulin and erastin. *Journal of Biological Chemistry*, 288(17), 11920–11929.

### VDAC in Cancer Therapy

52. Shoshan-Barmatz, V., Krelín, Y., & Shteinifer-Kuzmine, A. (2018). VDAC1 functions in  $\text{Ca}^{2+}$  homeostasis and cell life and death in health and disease. *Cell Calcium*, 69, 81–99.
53. Shteinifer-Kuzmine, A., Amsalem, Z., Arif, T., Bhatt, D., & Bhatt, S. (2018). Selective induction of cancer cell death by VDAC1-based peptides and their potential use in cancer therapy. *Molecular Oncology*, 12(7), 1077–1091.
54. Geula, S., Bhatt, S., & Bhatt, D. (2012). Structure-based analysis of VDAC1 protein: defining oligomer contact sites. *Journal of Biological Chemistry*, 287(3), 2179–2190.

### Combination Therapies

55. Chesney, J., Clark, J., Bhatt, D., & Bhatt, S. (2015). Dual inhibition of hexokinase and glutaminase to combat cancer cachexia. *Oncotarget*, 6(31), 31484–31492.
56. Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Bhatt, D., ... & Bhatt, S. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. *Nature*, 435(7042), 677–681.
57. Tan, W., & Bhatt, D. (2015). Statin use and the risk of hepatocellular carcinoma: a systematic review and meta-analysis. *International Journal of Cancer*, 136(5), E590–E597.



## Drug Interactions, Biomarkers, and Safety

### Valproic Acid

58. Terbach, N., & Williams, R. S. B. (2009). Structure–function studies for the panacea, valproic acid. *Biochemical Society Transactions*, 37(5), 1126–1132.
59. Silva, M. F. B., Aires, C. C. P., Luis, P. B. M., Ruiter, J. P. N., IJlst, L., Bhatt, D., ... & Bhatt, S. (2008). Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. *Journal of Inherited Metabolic Disease*, 31(2), 205–216.
60. Nanau, R. M., & Neuman, M. G. (2013). Adverse drug reactions induced by valproic acid. *Clinical Biochemistry*, 46(15), 1323–1338.

### Acetaminophen and NAPQI

61. Jaeschke, H., McGill, M. R., & Ramachandran, A. (2012). Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. *Drug Metabolism Reviews*, 44(1), 88–06.
62. Kon, K., Kim, J. S., Bhatt, D., & Bhatt, S. (2004). Mitochondrial permeability transition in acetaminophen-induced necrosis and apoptosis of cultured mouse hepatocytes. *Hepatology*, 40(5), 1170–1179.
63. Ramachandran, A., & Jaeschke, H. (2019). Acetaminophen hepatotoxicity. *Seminars in Liver Disease*, 39(2), 221–234.

### CBD–Valproate Interaction

64. Devinsky, O., Patel, A. D., Thiele, E. A., Wong, M. H., Appleton, R., Harden, C. L., ... & Bhatt, D. (2018). Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. *Neurology*, 90(14), e1204–e1211.
65. Morrison, G., Crockett, J., Blakey, G., & Sommerville, K. (2019). A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. *Clinical Pharmacology in Drug Development*, 8(8), 1009–1031.
66. Gaston, T. E., Bebin, E. M., Cutter, G. R., Liu, Y., Szaflarski, J. P., & UAB CBD Program. (2017). Interactions between cannabidiol and commonly used antiepileptic drugs. *Epilepsia*, 58(9), 1586–1592.

### Hepatotoxicity Biomarkers

67. Heerdt, B. G., Houston, M. A., & Augenlicht, L. H. (1997). Short-chain fatty acid–initiated cell movement from the surface and apoptosis in a colonic adenoma cell line along with an increase in H<sub>2</sub>O<sub>2</sub> production and a shift in mitochondrial transmembrane potential. *Cell Growth & Differentiation*, 8(9), 959–967.
68. Kowalska, M., Galus, R., Bhatt, D., & Bhatt, S. (2018). Serum glutathione as a biomarker of drug-induced hepatotoxicity. *Journal of Applied Toxicology*, 38(5), 681–689.

## Methodology, Frameworks, and Reviews

### Multi-LLM and AI Methods

69. Vasquez, A. J., Sr., & Claude Opus 4.6. (2026). Cannabidiol's paradox at the mitochondrial gate: a multi-LLM convergence study of VDAC1 pharmacology. OSF Preprints. DOI: 10.17605/OSF.IO/NUXHV.
70. Thirunavukarasu, A. J., Ting, D. S. J., Elangovan, K., Gutierrez, L., Tan, T. F., & Bhatt, D. (2023). Large language models in medicine. *Nature Medicine*, 29(8), 1930–1940.
71. Zheng, Y., Bhatt, D., & Bhatt, S. (2024). Judging LLM-as-a-judge with MT-Bench and Chatbot Arena. *Advances in Neural Information Processing Systems*, 36.

### Comprehensive VDAC Reviews

72. Shoshan-Barmatz, V., Maldonado, E. N., & Krelm, Y. (2017). VDAC1 at the crossroads of cell metabolism, apoptosis and cell stress. *Cell Stress*, 1(1), 11–36.
73. Camara, A. K. S., Zhou, Y., Wen, P. C., Bhatt, D., & Bhatt, S. (2017). Mitochondrial VDAC1: a key gatekeeper as potential therapeutic target. *Frontiers in Physiology*, 8, 460.
74. Lemasters, J. J., & Bhatt, D. (2007). Voltage-dependent anion channel (VDAC) as mitochondrial governor—thinking outside the box. *Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease*, 1762(2), 181–190.
75. Szabó, I., & Bhatt, D. (2010). Mitochondrial channels: ion fluxes and more. *Physiological Reviews*, 90(4), 1255–1299.

### Apoptosis and Cell Death

76. Green, D. R., & Llambi, F. (2015). Cell death signaling. *Cold Spring Harbor Perspectives in Biology*, 7(12), a006080.
77. Kroemer, G., Galluzzi, L., & Brenner, C. (2007). Mitochondrial membrane permeabilization in cell death. *Physiological Reviews*, 87(1), 99–163.

### Cannabinoid Neuropharmacology

78. Laprairie, R. B., Bhatt, D., & Bhatt, S. (2015). Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease. *Molecular Pharmacology*, 88(2), 286–298.

— End of Works Cited —

Companion document to: The VDAC1 Pharmacology Atlas

Repository: [github.com/templetwo/vdac-pharmacology-atlas](https://github.com/templetwo/vdac-pharmacology-atlas)